0001104659-21-128639.txt : 20211021 0001104659-21-128639.hdr.sgml : 20211021 20211021204952 ACCESSION NUMBER: 0001104659-21-128639 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211021 FILED AS OF DATE: 20211021 DATE AS OF CHANGE: 20211021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAY CITY CAPITAL LLC CENTRAL INDEX KEY: 0001288452 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40925 FILM NUMBER: 211338453 BUSINESS ADDRESS: STREET 1: 750 BATTERY STREET STE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 BUSINESS PHONE: 415.676.3830 MAIL ADDRESS: STREET 1: 750 BATTERY STREET STE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 FORMER NAME: FORMER CONFORMED NAME: BAY CITY CAPITAL FUND LLC DATE OF NAME CHANGE: 20040423 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xilio Therapeutics, Inc. CENTRAL INDEX KEY: 0001840233 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851623397 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-833-1027 MAIL ADDRESS: STREET 1: 828 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 3 1 tm2130646-12_3seq1.xml OWNERSHIP DOCUMENT X0206 3 2021-10-21 0 0001840233 Xilio Therapeutics, Inc. XLO 0001288452 BAY CITY CAPITAL LLC 1000 4TH STREET, SUITE 500 SAN RAFAEL CA 94901 0 0 1 0 Series B Preferred Stock Common Stock 665696 I See footnotes Series C Preferred Stock Common Stock 151294 I See footnotes The Series B Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date. The Series C Preferred Stock automatically converts into the number of shares of Common Stock as shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date. Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co. Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein. /s/ Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership, By: Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company, its General Partner, By: Fred Craves, Director 2021-10-21 /s/ Bay City Capital LLC, a Delaware limited liability company, By: Fred Craves, Managing Director 2021-10-21